Compare

Kuros Biosciences AG/€KURN

1D1W1M3M6MYTD1Y5YMAX

About Kuros Biosciences AG

Kuros Biosciences AG is a biotechnology company based in Switzerland, focused on the development of products for tissue repair and regeneration. Core to its business are biomaterial-based products designed to support bone healing in specific medical conditions. Its product portfolio includes innovative solutions like MagnetOs, used for spinal fusion; it is designed to enhance the body’s natural bone healing process. The company, headquartered in Schlieren, Switzerland, leverages its proprietary technologies to target significant unmet medical needs, positioning itself in the niche market of orthobiologics. Kuros Biosciences emphasizes innovation in biologics and synthetic solutions, aiming for a competitive edge in the healthcare sector.
Ticker
€KURN
Sector
Health
Primary listing
XGAT
Employees
213
Headquarters
Schlieren, Switzerland
Website
www.kurosbio.com

KURN Metrics

BasicAdvanced
€851M
108.91
€0.20
0.76
-

Bulls say / Bears say

Medical-device sales rose 40% in the first nine months of 2026, while adjusted EBITDA grew 68%; Kuros raised its full-year sales-growth guidance to 36–40% and expects an adjusted EBITDA margin above 14.5%. (Kuros Biosciences)
MagnetOs is gaining commercial traction: Kuros said it became the third-largest bone-graft brand by US revenue, with more than 150,000 patients treated worldwide. Its use is also spreading into extremities and trauma, broadening the potential beyond spine procedures. (Kuros Biosciences)
The Alpharetta, Georgia plant began commercial production in October, giving Kuros a second manufacturing site alongside the Netherlands. Local production in its largest market could add capacity and reduce supply-chain exposure as sales grow. (Kuros Biosciences)
The business remains heavily exposed to the US, which accounted for about 95% of revenue at the half-year. International sales are smaller and can be uneven because Kuros relies on distributors and some markets faced regulatory issues. (Investing.com)
The adjusted-earnings headline needs scrutiny: nine-month adjusted EBITDA was USD 20.6 million, versus group EBITDA of USD 13.5 million. Kuros says its adjusted measure excludes items including recurring share-based compensation and tariff-related costs, so it is not the same as reported operating performance. (Kuros Biosciences)
The larger prospective trials have not yet reported comparative outcomes: PROOF was 97% enrolled, PRECISE 55% and ASTRA 18%. Until results arrive, the clinical case for MagnetOs still depends partly on evidence that has not been confirmed in these studies. (OrthoEvidence, Kuros Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

Funds containing KURN

Funds
Fund name
Fund size
€KURN weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.04%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.04%
Xtrackers MSCI World Small Cap$XSWC
$183M0.00%
SPDR MSCI All Country World IM€SPYI
$7.7B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.